Tempus AI (NASDAQ:TEM) Director Sells $147,015.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Jennifer Doudna sold 2,673 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $147,015.00. Following the completion of the sale, the director owned 25,942 shares in the company, valued at approximately $1,426,810. The trade was a 9.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Down 2.2%

Shares of Tempus AI stock opened at $60.27 on Friday. The firm’s 50 day moving average is $50.38 and its 200 day moving average is $54.52. The firm has a market capitalization of $10.82 billion, a PE ratio of -35.04 and a beta of 3.46. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The business had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm’s revenue was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.24) EPS. Equities research analysts forecast that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TEM. GC Wealth Management RIA LLC bought a new position in Tempus AI during the 4th quarter worth approximately $399,267,000. Voloridge Investment Management LLC boosted its stake in shares of Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after purchasing an additional 1,039,176 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Tempus AI by 312.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock valued at $102,869,000 after purchasing an additional 965,730 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Tempus AI during the second quarter worth $54,020,000. Finally, Amova Asset Management Americas Inc. increased its position in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares during the period. 24.22% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TEM. Weiss Ratings restated a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Wolfe Research assumed coverage on Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. TD Cowen lifted their price target on Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Jefferies Financial Group initiated coverage on Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research report on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $68.54.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.